Checkpoint Therapeutics, Inc. (CKPT)

Compare

3.3900

-0.2800

(-7.63%)

At close: December 16 at 4:00:01 PM EST

3.3900

0.00

(0.00%)

After hours: 7:53:46 PM EST

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection

On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Unloxcyt is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. The recommended commercial dosage of Unloxcyt is 1,200 mg administered as an intravenous infusion over 60 minute

Benzinga 10 hours ago

CKPT
-7.63%
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or curative r

GlobeNewswire 3 days ago

FBIO
-4.64%
FBIOP

CKPT
-7.63%
Checkpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)

Checkpoint Therapeutics ( NASDAQ:CKPT ) Third Quarter 2024 Results Key Financial Results Net loss: US$9.73m (loss...

Simply Wall St. last month

CKPT
-7.63%
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates. “With the Prescription Drug User Fee Act (“PDUFA”) goal date set for next month, we await the decision by t

GlobeNewswire last month

FBIO
-4.64%
FBIOP

CKPT
-7.63%
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation of longer-term data from its pivotal trial of cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, in locally advanced and metastatic cutaneous squamous cell carcinoma (“cSCC”)

GlobeNewswire 2 months ago

CKPT
-7.63%
FBIO
-4.64%
FBIOP
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 10:00 a.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference. A webcas

GlobeNewswire 3 months ago

CKPT
-7.63%
FBIO
-4.64%
FBIOP
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock

Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 3 months ago

CKPT
-7.63%
Individual investors account for 57% of Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) ownership, while public companies account for 9.8%

Key Insights Checkpoint Therapeutics' significant individual investors ownership suggests that the key decisions are...

Simply Wall St. 4 months ago

CKPT
-7.63%
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of December 28, 2024 MIAMI, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-te

GlobeNewswire 4 months ago

FBIO
-4.64%
FBIOP

DERM
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2024, and recent corporate updates. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “We’ve made significant recent progress as we seek approval of cosibelimab as a potential new treatment for patients with metastatic or local

GlobeNewswire 4 months ago

FBIO
-4.64%
FBIOP

CKPT
-7.63%
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

PDUFA goal date of December 28, 2024 set by FDAWALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Checkpoint’s resubmission of its Biologics License Application (“BLA”) for cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, as a potential new treatment for adults with m

GlobeNewswire 4 months ago

CKPT
-7.63%
FBIO
-4.64%
FBIOP
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoint Therapeutics ("Checkpoint") (Nasdaq: CKPT) have announced a collaboration to explore the combined therapeutic potential of cosibelimab, Checkpoint’s anti-PD-L1 antibody with dual mechanism of action, with GC Cell’s Immuncell

GlobeNewswire 4 months ago

144510.KQ

FBIO
-4.64%
FBIOP
Checkpoint Therapeutics Resubmits Biologics License Application for Cosibelimab, Launches $12 Million Direct Share Offering

Checkpoint Therapeutics Resubmits Biologics License Application for Cosibelimab, Launches $12 Million Direct Share Offering

PREMIUM
MT Newswires 5 months ago

CKPT
-7.63%
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 5,853,659 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.05 per share of common stock (or per common stock equiva

GlobeNewswire 5 months ago

CKPT
-7.63%
FBIO
-4.64%
FBIOP
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma

GlobeNewswire 5 months ago

CKPT
-7.63%
FBIO
-4.64%
FBIOP
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its biologics license application (“BLA”) resubmission strategy for cosibelimab. Accordingly, Checkpoint plans to move forward with a mid-year BLA resubmission seeking the U.S. marketing approval for cosibelimab as a potential new treatm

GlobeNewswire 5 months ago

CKPT
-7.63%
FBIO
-4.64%
FBIOP
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET. Checkpoint will also attend in-person one-on-one meetings during the conference. A w

GlobeNewswire 7 months ago

FBIO
-4.64%
FBIOP

CKPT
-7.63%
Checkpoint Therapeutics First Quarter 2024 Earnings: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023)

Checkpoint Therapeutics ( NASDAQ:CKPT ) First Quarter 2024 Results Key Financial Results Net loss: US$10.9m (loss...

Simply Wall St. 7 months ago

CKPT
-7.63%
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “Over the past few months, we have worked closely with our third-party contract manufacturing organization (“CMO”) for cosibelimab to resolve

GlobeNewswire 7 months ago

FBIO
-4.64%
FBIOP

CKPT
-7.63%
Checkpoint Therapeutics Full Year 2023 Earnings: Misses Expectations

Checkpoint Therapeutics ( NASDAQ:CKPT ) Full Year 2023 Results Key Financial Results Net loss: US$51.8m (loss narrowed...

Simply Wall St. 8 months ago

CKPT
-7.63%

Performance Overview

Return	CKPT	S&P 500
YTD	+48.03%	+27.34%
1-Year	+2.11%	+28.71%
3-Year	-88.31%	+28.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Checkpoint Therapeutics, Inc. (CKPT)

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

Checkpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock

Individual investors account for 57% of Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) ownership, while public companies account for 9.8%

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

Checkpoint Therapeutics Resubmits Biologics License Application for Cosibelimab, Launches $12 Million Direct Share Offering

Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Checkpoint Therapeutics First Quarter 2024 Earnings: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023)

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

Checkpoint Therapeutics Full Year 2023 Earnings: Misses Expectations

Performance Overview